Rogers Corp. Dl 1 Stock
Rogers Corp. Dl 1 Stock
The Rogers Corp. Dl 1 price is unchanged compared to yesterday.
Criterium "Non-cyclic/Cyclic" is seen as the biggest plus for Rogers Corp. Dl 1 stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Rogers Corp. Dl 1 in the next few years
Pros
?
S********** s********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Rogers Corp. Dl 1 vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Rogers Corp. Dl 1 | 0.000% | -4.464% | -14.400% | 86.087% | 35.443% | -24.113% | -33.125% |
| Vishay Intertechnology Inc. | 3.170% | -5.992% | -23.943% | 122.665% | 142.795% | 22.024% | 64.439% |
| Universal Display Corp. | 0.200% | -0.430% | -0.743% | -44.619% | -31.807% | -45.425% | -64.050% |
| Silicon Labs Inc. | -1.060% | -1.064% | -0.535% | 64.602% | 67.568% | 44.186% | 41.985% |
News
iRadimed Q2 Earnings Call Highlights
Key Points
- Interested in iRadimed Corporation? Here are five stocks we like better.
- iRadimed’s new 3870 pump is seeing strong demand: Second-quarter bookings exceeded shipments by more than
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
Key Points
- Interested in Avalyn Pharma Inc.? Here are five stocks we like better.
- Avalyn Pharma is pursuing inhaled versions of approved pulmonary fibrosis drugs to reduce side effects that
IRADIMED's CEO Is Selling Steadily — The Plan, Not the Stock, Is Driving It
Roger E. Susi, CEO, President, and Chairman of IRADIMED CORPORATION (NASDAQ:IRMD), reported the indirect sale of 7,500 shares of common stock across multiple open-market transactions on May 26, 2026
